CVR: 26058708
Previous names: JUT NR. 2181 A/S
ORIFARM A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2001. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named JUT NR. 2181 A/S. The management consists of Thomas Brandhof. The company is owned by ORIFARM PI A/S. The company has 46 employees. In 2025, the company reported revenue of DKK 1,174,659,000 and a net result of DKK 9,727,000 compared with DKK 14,865,000 the year before. Equity amounted to DKK 44,048,000.
The financial health of ORIFARM A/S shows signs of instability, with a notable decline in both revenue and profit over the past two years. Revenue decreased from 1,575,946,000 DKK in 2023 to 1,174,659,000 DKK in 2025, while profit also fell from 18,874,000 DKK to 9,727,000 DKK in the same period. Although equity has remained relatively stable, decreasing from 76,256,000 DKK to 44,048,000 DKK, the declining profit margins raise concerns about operational efficiency. Positioned within the wholesale trade of medicinal products and healthcare items, ORIFARM A/S faces challenges that may impact its competitive standing in the industry.
AI-generated summary
Your company? Claim the profile and show your logo, website and social channels — for free.
Claim this profileSelskabets formål er at foretage salg af parallelimporterede lægemidler i Danmark.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1.2 mia. | 9.7 mio. | 148.1 mio. | 44 mio. | 37 | |
| 2024 | 1.2 mia. | 14.9 mio. | 150.4 mio. | 53.9 mio. | 37 | |
| 2023 | 1.6 mia. | 18.9 mio. | 301.8 mio. | 76.3 mio. | 37 | |
| 2022 | 1.4 mia. | 9.9 mio. | 421.6 mio. | 57.4 mio. | 34 | |
| 2021 | 1.5 mia. | 8.2 mio. | 195.4 mio. | 47.4 mio. | 40 | |
| 2020 | 1.2 mia. | 6.6 mio. | 195.1 mio. | 42.3 mio. | 42 | |
| 2019 | 1.2 mia. | 5.1 mio. | 175.3 mio. | 35.7 mio. | 38 | |
| 2018 | 1.3 mia. | 4.3 mio. | 194.2 mio. | 40.6 mio. | 45 | |
| 2017 | 1.2 mia. | 4.4 mio. | 232 mio. | 36.3 mio. | 42 | |
| 2016 | 1.2 mia. | 3.6 mio. | 312.4 mio. | 31.9 mio. | 72 | |
| 2015 | 1 mia. | 5.4 mio. | 194.8 mio. | 28.2 mio. | - | |
| 2014 | 1.1 mia. | 4.4 mio. | 218.9 mio. | 22.8 mio. | - | |
| 2013 | 1.1 mia. | 4.5 mio. | 213.8 mio. | 18.4 mio. | - |
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorCompared to 412 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
2 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Screen owners and management against the Danish FSA's official PEP lists
ORIFARM A/S has won the tender "Udbudsnummer 1" issued by Amgros I/S worth 3,222,720 DKK.
As of June 2, 2026, Birgitte Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2025. Revenue came to DKK 1,174,659,000, and the net result was DKK 9,727,000.
ORIFARM A/S has won the tender "Udbudsnummer 2" issued by Amgros I/S worth 75,600,000 DKK.
As of October 20, 2025, Nicki Lund Kristensen has joined the board of directors of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2024. Revenue came to DKK 1,223,777,000, and the net result was DKK 14,865,000.
As of March 17, 2025, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of March 17, 2025, Mads Fink Eriksen has joined the board of directors of ORIFARM A/S.
As of March 17, 2025, Erik Sandberg has left the board of directors of ORIFARM A/S.
As of March 16, 2025, Hans Carl Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2023. Revenue came to DKK 1,575,946,000, and the net result was DKK 18,874,000.
ORIFARM A/S has published its annual report for 2022. Revenue came to DKK 1,404,798,000, and the net result was DKK 9,941,000.
ORIFARM A/S has published its annual report for 2021. Revenue came to DKK 1,493,622,000, and the net result was DKK 8,190,000.
ORIFARM A/S has published its annual report for 2020. Revenue came to DKK 1,180,912,000, and the net result was DKK 6,563,000.
ORIFARM A/S has published its annual report for 2019. Revenue came to DKK 1,200,155,000, and the net result was DKK 5,096,000.
ORIFARM A/S has published its annual report for 2018. Revenue came to DKK 1,250,457,000, and the net result was DKK 4,295,000.
As of February 1, 2019, Jens Peter Nielsen has left the board of directors of ORIFARM A/S.
As of February 1, 2019, Thomas Brandhof is registered as adm. dir. of ORIFARM A/S.
As of February 1, 2019, Tine Søndergaard Jensen has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2017. Revenue came to DKK 1,192,494,000, and the net result was DKK 4,424,000.
ORIFARM A/S has published its annual report for 2016. Revenue came to DKK 1,202,590,000, and the net result was DKK 3,640,000.
ORIFARM A/S has published its annual report for 2015. Revenue came to DKK 1,035,134,000, and the net result was DKK 5,442,000.
As of August 27, 2015, Jens Peter Nielsen has joined the board of directors of ORIFARM A/S.
As of August 27, 2015, Anna Rehman Linder has left the board of directors of ORIFARM A/S.
As of August 27, 2015, Tine Søndergaard Jensen is registered as adm. dir. of ORIFARM A/S.
As of August 27, 2015, Jens Peter Nielsen has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2014. Revenue came to DKK 1,149,174,000, and the net result was DKK 4,431,000.
ORIFARM A/S has published its annual report for 2013. Revenue came to DKK 1,078,460,000, and the net result was DKK 4,473,000.
As of April 9, 2014, Birgitte Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Erik Sandberg has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Anna Rehman Linder has joined the board of directors of ORIFARM A/S.
As of April 9, 2014, Hans Christian Eberhard Groth Teisen has left the board of directors of ORIFARM A/S.
As of April 9, 2014, Jens Peter Nielsen is registered as adm. dir. of ORIFARM A/S.
As of April 9, 2014, Erik Sandberg has stepped down as adm. dir. of ORIFARM A/S.
ORIFARM A/S has published its annual report for 2012.
As of December 21, 2012, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of December 21, 2012, Anders Carl Norstrand has left the board of directors of ORIFARM A/S.
As of December 21, 2012, Erik Sandberg is registered as adm. dir. of ORIFARM A/S.
As of December 21, 2012, Hans Carl Bøgh-Sørensen has stepped down as adm. dir. of ORIFARM A/S.
As of July 5, 2012, Hans Christian Eberhard Groth Teisen has joined the board of directors of ORIFARM A/S.
As of July 5, 2012, Ole Ibsen has left the board of directors of ORIFARM A/S.
As of October 13, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ORIFARM A/S.
As of October 13, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of ORIFARM A/S.
As of April 15, 2008, Ole Ibsen has joined the board of directors of ORIFARM A/S.
As of April 14, 2008, Per Munk Laustsen has left the board of directors of ORIFARM A/S.
As of January 27, 2005, Anders Carl Norstrand has joined the board of directors of ORIFARM A/S.
As of January 27, 2005, John Morell Frellsen has left the board of directors of ORIFARM A/S.
As of January 27, 2005, Hans Carl Bøgh-Sørensen is registered as adm. dir. of ORIFARM A/S.
As of October 20, 2003, Per Munk Laustsen has joined the board of directors of ORIFARM A/S.
As of October 20, 2003, John Morell Frellsen has joined the board of directors of ORIFARM A/S.
As of October 20, 2003, Ole Michael Friis has left the board of directors of ORIFARM A/S.
As of October 20, 2003, Hans Carl Bøgh-Sørensen has left the board of directors of ORIFARM A/S.
As of September 12, 2003, ORIFARM PI A/S is registered as an owner of ORIFARM A/S with an ownership share of 100%.
As of May 31, 2003, Niels Thorborg has left the board of directors of ORIFARM A/S.
On January 5, 2002, the company changed its name from JUT NR. 2181 A/S to ORIFARM A/S.
As of November 1, 2001, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of ORIFARM A/S.
As of November 1, 2001, Poul Bak Revisionsfirma I/S Postboks 428 has stepped down as auditor of ORIFARM A/S.
As of November 1, 2001, Ole Michael Friis has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Niels Thorborg has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Hans Carl Bøgh-Sørensen has joined the board of directors of ORIFARM A/S.
As of November 1, 2001, Henrik Steen Jensen has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Steffen Ebdrup has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Erik Jensen has left the board of directors of ORIFARM A/S.
As of November 1, 2001, Erik Jensen has stepped down as director of ORIFARM A/S.
As of April 1, 2001, Poul Bak Revisionsfirma I/S Postboks 428 has been appointed auditor of ORIFARM A/S.
As of April 1, 2001, Henrik Steen Jensen has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Steffen Ebdrup has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Erik Jensen has joined the board of directors of ORIFARM A/S.
As of April 1, 2001, Erik Jensen is registered as director of ORIFARM A/S.
ORIFARM A/S was founded on April 1, 2001.
Companies in the same industry and area
CVR 36089210
CVR 17153684
CVR 25674030
CVR 45236145
CVR 44825775
companydata.dk